Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11218137 | 0.81 | PTPN1 (0.57) | PTPN1 | |
| SCHEMBL8594791 | 0.80 | SRC (0.54) | SRC | |
| SCHEMBL11050071 | 0.80 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL4530526 | 0.79 | SRC (0.52) | SRC | |
| SCHEMBL2985777 | 0.78 | PTPN1 (0.53) | PTPN1 | |
| SCHEMBL28018621 | 0.78 | SRC (0.55) | SRC | |
| SCHEMBL18227970 | 0.78 | KDM4E (0.47) | CA2FAAH | |
| SCHEMBL28199506 | 0.78 | KDM4E (0.53) | SRC | |
| SCHEMBL27915558 | 0.76 | NPC1 (0.40) | TLR8SRC | |
| SCHEMBL24958682 | 0.75 | CA2 (0.51) | CA2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101193862-B | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD | 2013-08-21 | — | — | CN | disclosed |
| CN-101193862-A | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2008-06-04 | — | — | CN | disclosed |
| US-6903134-B2 | Formulation comprising benzofuranone derivatives for protection against oxidative stress | MERCK PATENT GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1250331-B1 | FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-20030060426-A1 | Formulation for protection against oxidative stress containing benzofuranone derivatives | MERCK PATENT GMBH (DE) | 2003-03-27 | — | — | US | disclosed |
| EP-1250331-A1 | FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES | MERCK PATENT GmbH (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001055128-A1 | FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060426-A1 | Formulation for protection against oxidative stress containing benzofuranone derivatives | NQO1, NFE2L2, GPX4 | TLR8 2775/4885SRC 3375/4885CA2 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.